Zepbound vs Mounjaro 2026

1. Identical molecule + dose proof

Zepbound (FDA-approved 2023) and Mounjaro (FDA-approved 2022) both contain tirzepatide as their active pharmaceutical ingredient. The molecules are not similar — they are identical. Same chemical structure, same molecular weight, same pharmacokinetic profile, same receptor binding (dual GIP and GLP-1 receptor agonism).

Both come in the same dose strengths:

• 2.5 mg (starter)
• 5 mg
• 7.5 mg
• 10 mg
• 12.5 mg
• 15 mg (maintenance/maximum)

Both administered by once-weekly subcutaneous injection. Both manufactured by Eli Lilly in the same facilities. Most patients couldn't tell the difference if you swapped the labeled pens.

2. FDA indication differences

The split exists because FDA approves drugs for specific indications (medical conditions). Eli Lilly chose to submit tirzepatide for two parallel approvals under different brand names, then market each to its specific indication audience.

Zepbound — FDA approved for:

• Chronic weight management in adults with BMI ≥30, or BMI ≥27 with a weight-related comorbidity (2023)
• Moderate-to-severe obstructive sleep apnea in adults with obesity (2024)

Mounjaro — FDA approved for:

• Type 2 diabetes mellitus in adults (2022)
• Type 2 diabetes in children aged 10+ (2024 pediatric expansion)

One molecule, two brand names, four distinct indications across them. Different prescriber populations (obesity medicine + sleep apnea specialists for Zepbound; endocrinologists + primary care for Mounjaro diabetes).

3. Side-by-side comparison table

4. Weight loss + A1C efficacy data

Because the molecule is identical, efficacy is identical when dose-matched:

Weight loss (SURMOUNT-1, Zepbound branding)

• 2.5mg: ~5% body weight loss at 72 weeks
• 5mg: ~15% body weight loss at 72 weeks
• 10mg: ~19% body weight loss at 72 weeks
• 15mg: 22.5% body weight loss at 72 weeks (cohort average)

A1C reduction (SURPASS-2, Mounjaro branding)

• 5mg: −1.9 percentage points at 40 weeks
• 10mg: −2.1 percentage points at 40 weeks
• 15mg: −2.3 percentage points at 40 weeks (vs −1.9 for semaglutide 1mg)

In diabetic patients on Mounjaro, weight loss accompanies the A1C reduction: roughly 6-12 kg (13-26 lbs) at the higher doses. The pattern is identical — the same molecule produces the same effects regardless of label.

5. Side effects are identical

Identical molecule = identical side-effect profile. The most common (occurring at similar rates in both SURMOUNT and SURPASS):

• Nausea (~30%)
• Diarrhea (~20%)
• Constipation (~10%)
• Vomiting (~10%)
• Decreased appetite (most patients — desired effect)
• Fatigue (~5-10%)

Less common but notable: pancreatitis (uncommon, <1%), gallbladder events (uncommon), worsening diabetic retinopathy in patients with pre-existing severe retinopathy (rapid A1C drop). Visit our symptom management guides for week-by-week titration support.

6. Cost + cash-pay programs

Cash-pay is where Zepbound and Mounjaro diverge dramatically in 2026:

Zepbound

• List price: ~$1,086/month for autoinjector pens
• LillyDirect single-dose vials: $349/month (2.5mg) up to $499/month (15mg) — cash-pay, no insurance billing, anyone can access
• LillyCares savings card for commercially-insured patients: $0-25/month copay

Mounjaro

• List price: ~$1,023/month for autoinjector pens
• No equivalent LillyDirect cash-pay vial program
• LillyCares savings card for commercially-insured: $0-25/month copay

For cash-pay patients, Zepbound at LillyDirect $349-499 is the clear winner. For insured diabetic patients, Mounjaro coverage typically more reliable.

7. Insurance coverage pathways

Insurance plans classify and cover GLP-1s based on FDA-approved indication, which creates the asymmetry:

Mounjaro coverage (typical)

• Covered by most commercial plans for type 2 diabetes
• Covered by Medicare Part D for type 2 diabetes (statutory)
• Covered by most state Medicaids for type 2 diabetes
• Off-label use for weight loss is increasingly rejected by insurers in 2026

Zepbound coverage (typical)

• Covered by fewer commercial plans — many exclude weight-loss drugs
• NOT covered by Medicare Part D for weight loss (MMA 2003 statutory exclusion)
• State Medicaid coverage varies (~13 states cover for weight as of 2026)
• Covered for obstructive sleep apnea where eligible (newer indication, expanding)

See our Insurance Coverage 2026 guide for the full coverage landscape + 3-step appeal protocol.

8. Switching between them

Switching from Mounjaro to Zepbound (or vice versa) is pharmacologically zero-risk: same drug, same dose. The complexity is administrative:

1. Your prescriber writes the new brand name script
2. If your dose is established, you continue at the same dose without restart
3. Schedule first injection 7 days after the last of the old brand (standard weekly cycle)
4. Insurance authorization may need to be redone if you're shifting indication categories

Common scenarios for switching:

• You started Mounjaro off-label for weight; insurance now requires Zepbound for that purpose
• You started Zepbound for weight; you developed type 2 diabetes; insurance now reimburses Mounjaro
• Cost optimization — Zepbound LillyDirect vials are cheaper than Mounjaro retail cash-pay

9. Which to ask your prescriber for

• You have type 2 diabetes: Mounjaro (on-label, insurance-friendly)
• You have obesity (BMI ≥30) or overweight (BMI ≥27) + comorbidity: Zepbound (on-label, including LillyDirect cash-pay access)
• You have obstructive sleep apnea with obesity: Zepbound (specific indication)
• You have both T2D and obesity: Depends — some prescribers favor Mounjaro for the diabetes indication coverage, then patient gets weight benefit. Others prefer Zepbound for the broader weight indication. Discuss with prescriber.
• You're cash-pay only and don't have diabetes: Zepbound via LillyDirect ($349-499/month) — far cheaper than Mounjaro cash-pay retail.

10. Frequently asked questions

Are Zepbound and Mounjaro the same drug?

Yes — both contain identical tirzepatide molecules at identical doses (2.5/5/7.5/10/12.5/15 mg weekly), manufactured by Eli Lilly. The only differences are FDA-approved indication (Zepbound = chronic weight management + obstructive sleep apnea; Mounjaro = type 2 diabetes), branding, insurance coverage pathway, and cash-pay program access.

Can I get Mounjaro for weight loss?

Mounjaro is FDA-approved only for type 2 diabetes. Off-label use for weight loss exists but is increasingly being rejected by insurance plans in 2026. If you don't have diabetes and want tirzepatide for weight loss, Zepbound (the on-label option) is the correct prescription. Your prescriber writes one or the other based on your indication.

Is Zepbound or Mounjaro cheaper without insurance?

Zepbound has the cheaper cash-pay option in 2026: LillyDirect single-dose vials at $349-499/month, available to anyone (no insurance required). Mounjaro doesn't have an equivalent direct cash-pay program at the same pricing. List prices are similar (~$1,086 for Zepbound vs ~$1,023 for Mounjaro), but real-world cash-pay favors Zepbound via LillyDirect.

Does insurance cover Zepbound differently than Mounjaro?

Yes, dramatically. Insurance plans classify medications by FDA-approved use. Mounjaro typically gets covered for type 2 diabetes (most plans cover diabetes drugs). Zepbound for weight management is covered by fewer plans — many employer plans exclude obesity drugs entirely. Same molecule, completely different coverage pathways.

Will I get the same weight loss on Mounjaro as Zepbound?

Yes, when dose-matched. Both drugs use identical tirzepatide molecules. Zepbound 15mg achieved 22.5% average weight loss in SURMOUNT-1 over 72 weeks. Mounjaro at the same 15mg dose in SURPASS trials showed comparable weight outcomes in diabetic patients. The molecule doesn't know which label is on the box — pharmacologic effect is identical.

Should I switch from Mounjaro to Zepbound?

Three scenarios for switching: (1) Your indication changed — you now have a weight indication that wasn't there when you started; (2) Your insurance coverage changed — Zepbound now covered but Mounjaro isn't (or vice versa); (3) Cost optimization — you want LillyDirect access via Zepbound. The molecule transition is pharmacologically zero-risk (same drug, same dose). Insurance + prescriber paperwork is the only complexity.

• Editorial board reviewed
• CC BY 4.0 data
• FDA-source citations
• Affiliate disclosed

Coverage and pricing reflect mid-2026 publicly-stated information. Always confirm current pricing and insurance coverage directly with the provider and your insurer. GLP1Zoom is affiliate-disclosed. Full disclaimer.